UNDERSTANDING PERFORMANCE CHARACTERISTICS OF LIVE ATTENUATED VACCINES FOR THE PREVENTION AND CONTROL OF AFRICAN SWINE FEVERIN WILD BOAR AND DOMESTIC PIGS

Fonte Standard Gras
Identifiant

Unité de recherche

SEFRI

Numéro de projet

23.00633

Titre du projet

UNDERSTANDING PERFORMANCE CHARACTERISTICS OF LIVE ATTENUATED VACCINES FOR THE PREVENTION AND CONTROL OF AFRICAN SWINE FEVERIN WILD BOAR AND DOMESTIC PIGS

Textes relatifs à ce projet

	Allemand	Français	Italien	Anglais
Résumé des résultats (Abstract)	-	-	-

Textes saisis

Catégorie	Texte
Résumé des résultats (Abstract) (Anglais)	African swine fever (ASF) has recently transformed from an exotic disease to a panzootic threat to domestic and wild suids worldwide.Europe is currently facing different scenarios with front and point introductions, affected wild boar and domestic pig populations,epidemic and endemic situations. While our traditional prevention and control strategies work well with industrial pig farms, we quicklyreach our limits when we have to control the disease in the abundant wild boar population or in regions with a majority of backyardfarms. To turn the tide and to safeguard animal health, vaccines, especially oral vaccines for wild boar, could be the missing tool. Therehas been considerable progress in vaccine development and while we should continue to look for alternative approaches, we must nowalso dare to test the promising candidates beyond simple proof-of-concept studies. Only in this way can we generate the data basefor benefit-risk analysis of whether and how current generation vaccines could be employed. Along these lines, this project sets outto test the vaccine candidate "ASFV-G-?I177L" in safety and efficacy tests after oral and intramuscular application as prescribed byinternational guidelines. This vaccine candidate has shown safety and very good protection under laboratory conditions and has beenapplied in the field in Vietnam. As a backup option, other promising candidates, “ASFV-G-?MGF” and “ASFV-G-?9GL/UK, will betested in initial comparative trials. Accompanying the prescribed tests, our interdisciplinary consortium will characterize the protectiveimmune responses, target the optimization of oral immunization and model tailored vaccination strategies. The data body generated inthis project is crucial for benefit-risk-assessments at the level of all authorities entrusted with licensure and deployment of ASF vaccinesand for this reason, relevant stakeholders will be involved from the start to guarantee full exploitation of our data.

Catégorie

Texte

Résumé des résultats (Abstract)
(Anglais)

African swine fever (ASF) has recently transformed from an exotic disease to a panzootic threat to domestic and wild suids worldwide.Europe is currently facing different scenarios with front and point introductions, affected wild boar and domestic pig populations,epidemic and endemic situations. While our traditional prevention and control strategies work well with industrial pig farms, we quicklyreach our limits when we have to control the disease in the abundant wild boar population or in regions with a majority of backyardfarms. To turn the tide and to safeguard animal health, vaccines, especially oral vaccines for wild boar, could be the missing tool. Therehas been considerable progress in vaccine development and while we should continue to look for alternative approaches, we must nowalso dare to test the promising candidates beyond simple proof-of-concept studies. Only in this way can we generate the data basefor benefit-risk analysis of whether and how current generation vaccines could be employed. Along these lines, this project sets outto test the vaccine candidate "ASFV-G-?I177L" in safety and efficacy tests after oral and intramuscular application as prescribed byinternational guidelines. This vaccine candidate has shown safety and very good protection under laboratory conditions and has beenapplied in the field in Vietnam. As a backup option, other promising candidates, “ASFV-G-?MGF” and “ASFV-G-?9GL/UK, will betested in initial comparative trials. Accompanying the prescribed tests, our interdisciplinary consortium will characterize the protectiveimmune responses, target the optimization of oral immunization and model tailored vaccination strategies. The data body generated inthis project is crucial for benefit-risk-assessments at the level of all authorities entrusted with licensure and deployment of ASF vaccinesand for this reason, relevant stakeholders will be involved from the start to guarantee full exploitation of our data.